Catalase activity in Candida albicans exposed to antineoplastic drugs

Journal of Medical Microbiology

Volumn 55, Issue 3, 2006, Pages 259-262

  Linares, Carlos E B ^a   Griebeler, Deizi ^a   Cargnelutti, Denise ^a   Alves, Sydney H ^a   Morsch, Vera M ^a   Schetinger, Maria R C ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CATALASE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; METHOTREXATE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANDIDA ALBICANS; CONTROLLED STUDY; DOSE RESPONSE; DRUG RESISTANCE; ENZYME ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MYCOSIS; NONHUMAN; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; CANDIDA ALBICANS; CATALASE; HUMANS; KINETICS; METHOTREXATE;

EID: 33645102808     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.46263-0     Document Type: Article

References (22)

1. Abrahamsen, T. G., Widing, E., Glomstein, A. & Gaustad, P. (1992). Disseminated fungal disease resistant to fluconazole treatment in a child with leukemia. Scand J Infect Dis 24, 391-393.
2. Aebi, H. (1984). Catalase in vitro. Method Enzymol 105, 121-126.
3. Ahearn, D. G. & McGlohn, M. S. (1984). In vitro susceptibilities of sucrose-negative Candida tropicalis, Candida lusitaniae, and Candida norvegensis to amphotericin B, 5-fluorocytosine, miconazole and ketoconazole. J Clin Microbiol 19, 412-416.
4. Batey, M. A., Wright, J. G., Azzabi, A., Newell, D. R., Lind, M. J., Calvert, A. H. & Boddy, A. V. (2002). Population pharmacokinetics of adjuvant cyclophosphamide, methotrexale and 5-fluorouracil (CMF). Eur J Cancer 38, 1081-1089.
5. Bradford, M. M. (1976). A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248-254.
6. Brajtburg, J., Elberg, S., Kobayashi, G. S. & Medoff, G. (1988). Interference with effects of amphotericin B on Candida albicans cells by 2-chloroethyl-1-nitrosoureas. Antimicrob Agents Chemother 32, 327-330.
7. Conly, J., Rennie, R., Johson, J., Farah, S. & Hellman, L. (1992). Disseminated candidiasis due to amphotericin B-resistant Candida albicans. J Infect Dis 165, 761-764.
8. Davies, A., Brailsford, S., Broadley, K. & Beighton, D. (2002). Resistance amongst yeasts isolated from the oral cavities of patients with advanced cancer. Palliat Med 16, 527-531.
9. Dick, J. D., Merz, W. G. & Saral, R. (1980). Incidence of polyene resistant yeast recovered from clinical specimens. Antimicrob Agents Chemother 18, 158-163.
10. Egorin, M. J., Forrest, A., Belani, C. P., Ratain, M. J., Abrams, J. S. & Van Echo, D. A. (1989). A limited sampling strategy for cyclophosphamide pharmacokinetics. Cancer Res 49, 3129-3133.
11. Ghannoum, M. A. (1986). Effects of antineoplastic agents on growth, morphology and metabolism of Torulopsis glabrata. Mycopathologia 95, 175-181.
12. Lineweaver, H. & Burk, D. (1934). The determination of enzyme dissociation constant. J Am Chem Soc 116, 688.
13. Kerridge, D. & Nicholas, R. D. (1986). Drug resistance in the opportunistic pathogens Candida albicans and C. glabrata. J Antimicrob Chemother 18, 39-49.
14. Liliemark, J. & Peterson, C. (1991). Pharmacokinetic optimization of anticancer therapy. Clin Pharmacokinet 21, 213-231.
15. Morikawa, N., Mori, T., Abe, T., Ghoda, M., Takeyama, M. & Hori, S. (1997). Pharmacokinetics of methotrexate in plasma and cerebro-spinal fluid. Ann Pharmacother 31, 1153-1156.
16. Nakagawa, Y., Kanbe, T. & Mizuguchi, I. (2003). Disruption of the human pathogenic yeast Candida albicans catalase gene decreased survival in mouse-model infection and elevated susceptibility to higher temperature and to detergents. Microbiol Immunol 47, 395-403.
17. Nolte, F. S., Parkinson, T., Falconer, D. J., Dix, S., Williams, J., Gilmore, C., Geller, R. & Wingard, J. R. (1997). Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother 44, 196-199.
18. Salonen, J. H., Richardson, M. D., Gallacher, K., Issakainen, J., Helenius, H., Lehtonen, O. P. & Nikoskelainen, J. (2000). Fungal colonization of haematological patients receiving cytotoxic chemotherapy: emergence of azole-resistant Saccharomyces ccrevisiae. J Hosp Infect 45, 293-301.
19. Sarachek, A. & Henderson, L. A. (1991). Modification of responses of Candida albicans to cisplatin by membrane damaging antimycotic agents. Mycoses 34, 177-182.
20. Sokol-Anderson, M., Brajtburg, J. & Medoff, G. (1986). Amphotericin B induced oxidative damage and killing of Candida albicans. J Infect Dis 154, 76-83.
21. Sokol-Anderson, M., Sligh, J. E., Elberg, S., Brajtburg, J., Kobayashi, G. S. & Medoff, G. (1988). Role of cell defense against oxidative damage in the resistance of Candida albicans to the killing effect of amphotericin B. Antimicrob Agents Chemother 32, 702-705.
22. Vanden Bossche, H., Marichal, P. & Odds, C. F. (1994). Molecular mechanisms of drug resistance in fungi. Trends Microbiol 2, 393-400.